A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment.
Murugesan A, Smirnov A, Alonso AV, Buccioni M, Cui C, Dal Ben D, Francucci B, Lambertucci C, Marucci G, Volpini R, Konda Mani S, Devanesan S, AlSalhi MS, Yli-Harja O, Spinaci A, Kandhavelu M.
Murugesan A, et al.
Eur J Pharm Sci. 2025 Apr 1;207:107039. doi: 10.1016/j.ejps.2025.107039. Epub 2025 Feb 10.
Eur J Pharm Sci. 2025.
PMID: 39938810
Free article.
ANR 672 showed higher affinity toward A(2A)AR (K(i) = 1.02 0.06 nM) and exhibited significant IC(50) concentrations of 60-80 M, than FDA approved drug istredefylline. The A(2A)AR-ANR 672 interaction profile showed well-defined hydrogen bonds and hydrophobic contacts, indic …
ANR 672 showed higher affinity toward A(2A)AR (K(i) = 1.02 0.06 nM) and exhibited significant IC(50) concentrations of 60-80 M, than …